Keywords
Post-Stroke Fatigue, Scoping Review
Post-Stroke Fatigue, Scoping Review
In Table 2, we replaced the red and green colour keys with grey and white.
In Table 4, we added the effect sizes for interventional studies as reported in the original studies.
In the Discussion, we added the need for future research to include sensitivity analysis and the need for international standard reporting guidelines for measuring and reporting the outcomes. We suggested that future reviews should consider the impact of research on online delivery of interventions.
We changed `Limitations' to `Limitations and strengths' and added three key strengths of the current scoping review.
We changed 'Limitations' to 'Limitations and strengths' and added three strengths of the current scoping review.
See the authors' detailed response to the review by Carina U. Persson
See the authors' detailed response to the review by Nicola Hancock
Post-stroke fatigue (PSF) has been defined as ‘overwhelming feeling of exhaustion or tiredness’, which is unrelated to exertion, and does not typically improve with rest1. It is one of the most common outcomes of stroke and its prevalence varies between 25% and 85%; however, it is generally accepted that it affects 50% of people after stroke2. PSF is linked to undesirable stroke outcomes and affects patients’ participation in studies, adherence to medication, and effectiveness of rehabilitation3. This has a negative impact on patients’ quality of life and daily life activities4–7, and also contributes to the burden on family members and carers8.
Although researchers have attempted to explain PSF mechanisms9, its aetiology still remains unclear. This is partly because there are many contributing factors to PSF8,10–32, and each research team may focus only on some of the factors to find a route for preventing, treating or managing PSF. Any endeavour to find the most effective intervention in the research literature leads to a collection of heterogeneous interventions from physiotherapy33 and exercise34–38 to psychotherapy, pharmacotherapy, and recently laser therapy39–41.
As a systematic effort to review these scattered interventions, a Cochrane review42,43 compared all the tested PSF treatments to a control group, to standard care, or to each other, through reviewing randomised controlled trials (RCTs). This review concluded that there was insufficient evidence of the efficacy of the tested interventions in trials, and more robust research with adequate sample sizes was required42,43. Since then, more recent systematic reviews until 2019 have attempted to summarise the evidence of effectiveness of Modafinil, mindfulness training, a traditional Chinese medicine, and smart technologies, but still came to a similar conclusion to that of the Cochrane review in 201544–47.
As a result of such uncertainty, current clinical practice guidelines rely on low levels of evidence, such as expert consensus, to make recommendations for PSF48,49. However, the efforts to design and test treatments continue, which makes it necessary to keep up-to-date with new research and practice literature.
The objective of this review was to identify and summarise the most recent research literature related to PSF in order to update the evidence base. As there was an existing review covering the literature up until 201650, we only updated the literature not covered in this review.
In 2017, Hinkle et al.,50 published a review covering emerging evidence relating to the management of PSF, up to and including February 2016. Because of the comprehensiveness of this review, we only searched for literature published after 1st March 2016. As the search methods of the Hinkle et al., review were not reproducible, and the search strategies and results were not available, we contacted the corresponding author and their librarian on 15th October 2019. Since we did not receive a reply, we designed the search methods for the reported databases in order to capture the majority of the literature included in Hinkle et al.,’s review.
We followed Arksey and O’Malley framework51 for conducting this scoping review. We also used Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Extension for Scoping Reviews(PRISMA-ScR) for reporting52. The relevant PRSIMA-ScR checklist is available as Extended data and the flow diagram is reported in the Results section (Figure 1).
We ran a search to include studies in the English language only, between 1st March 2016 and 19th January 2020 (search date) in CINAHL via EBSCOhost, MEDLINE via Ovid SP, PubMed (excluding MEDLINE), and PsycINFO via Ovid. There were no limitations to document type (e.g. thesis), study completion status (e.g. ongoing), and publication status (e.g. unpublished) at the search stage. We report the search strategies for all databases in Extended data.
We imported the search results into EndNote X6 and de-duplicated them based on title, and additionally double-checked the automatically identified duplicates manually. Two reviewers (GA and FS) screened the results independently against the eligibility criteria using Rayyan, which is a recommended screening system53. Discrepancies were resolved through discussions or asking a third reviewer (AD).
Two reviewers (GA and FS) also investigated the full texts of relevant search results against the same criteria involving a third reviewer (AD) in case of disagreement. At full text screening stage, we also investigated the reference lists of the relevant studies to identify additional relevant studies. Since one study may have multiple reports or publications, we kept a record and cited all the reports of a single study to provide a better overview of the new research evidence.
We included the following studies:
- Studies of adult humans with PSF – any definition of PSF – at any stage of the stroke care continuum;
- Any interventional (clinical trial) or observational (cohort, case-control, and cross-sectional) studies, and clinical practice guidelines;
- Studies reporting findings that had not been included in the previous review;
- Studies included in relevant systematic reviews.
We excluded the following studies:
- Studies with case reports, case series, and qualitative design;
- Studies included in Hinkle et al., or results which repeated the summarised knowledge in that review;
- Studies of pre-clinical nature;
- Clinical studies where fatigue was reported only as a side effect of the treatment;
- Studies focusing on single muscle fatigue or muscle fatigue in general;
- Studies not focusing on fatigue and/or stroke or focusing on heat stroke, athletes’ fatigue or carers’ fatigue;
- Systematic or narrative or review papers;
- Ongoing studies or protocols with no results (listed and cited in this paper for further follow-up);
- Tool validation studies without reporting new findings on PSF.
One reviewer (GA) extracted and entered the data in Excel 2007 and the second reviewer (FS) checked the extracted and entered data against the full text and, if appropriate, corrected or amended the data.
For interventional studies, we extracted PICOS (participants, intervention, comparison, outcomes, and study design) and other data points:
- Study name and year;
- Clinical trial registration number (for further check on selective reporting bias);
- Country of origin;
- Number of centres;
- Patients: Number of patients, type of stroke, time passed after stroke;
- Intervention and controls: name of intervention and duration;
- Primary and secondary outcomes measures in general and fatigue measures in particular, outcome endpoints, and main findings related to PSF;
- Study design (single-arm clinical trial (CT), controlled clinical trial (CCT), or RCT);
For observational studies, we extracted:
- Study name and year;
- Clinical trial registration number (for further check on selective reporting bias);
- Country of origin;
- Number of centres;
- Patients: Number of patients, type of stroke, time passed after stroke;
- Primary and secondary outcomes measures in general and fatigue measures in particular, outcome endpoints, and main findings related to PSF;
- Study design (cohort, case-control, or cross-sectional).
For clinical practice guidelines, we extracted the following data:
We used RobotReviewer for assessing the risk of bias in the four categories of the Cochrane Risk of Bias tool54 for included RCTs. Although this automation system is reliable for checking the risk of bias for certain bias categories55,56, one of the reviewers (GA) also double-checked and revised RobotReviewer’s assessment and corrected the data where necessary. We also added a ‘selective reporting of outcomes’ category to the list of biases to cover the main biases in Cochrane Risk of Bias tool. Because of ‘scoping’ nature of this review and lack of time and resources, we did not assess the risk of bias for non-RCTs.
We summarised the data from the new relevant literature in tables. We did not proceed to a meta-analysis for fatigue outcomes due to the heterogeneity of studies. We checked if any of the interventional studies considered following the CONSORT57 for reporting RCTs or TIDieR checklist58 to report the components of new interventions.
The search identified 1021 results. After screening, we included 45 relevant records related to 24 studies and 6 guidelines (Figure 1).
The characteristics of included interventional studies have been charted in Table 1. The table shows eight RCTs some with multiple reports and one with a follow-up study59–73, one CCT74, and two single-arm trials75,76. All studies were based on single centre studies, except for West et al., (2019) which had two centres71. In studies that reported the intervention delivery details, the psychological interventions were delivered individually and face-to-face – rather than online – by psychologists. We also assessed the risk of bias for RCTs and reported the categories of risk in Table 2 with supporting statements in Extended data.
Study name | Country | Design | No. of participants | Stroke type | Time after stroke | Interventions | Duration of intervention | Delivered by | Delivery mode |
---|---|---|---|---|---|---|---|---|---|
Chen et al., 2016 | Taiwan | RCT | 41 | With CHF | 64.95±53.07 D | Inspiratory Muscle Training + TAU v. TAU | 10 W (5 D/W) | Respiratory Therapist | NR |
Chen et al., 2019 | Taiwan | RCT | 72 | Ischemic | NR | Mind-Body Exercise (Qigong) + TAU v. TAU | 10 D | Researchers | Individual |
Delva 2019 | Ukraine | CCT | 39 | Ischemic/TIA | ≥3 M | Acetylsalicylic Acid (Low Dose v. High Dose) | 3 M | NR | NR |
Liu et al., 2016 | Taiwan | RCT | 64 | Haemorrhagic /Infraction | ≥3 M | Astragalus membranaceus v. Placebo | 28 D | NR | NR |
Liu et al., 2018 | China | RCT | 140 | NR | NR | Vitamin C v. Wuling | 12 W | NR | NR |
MIDAS | Australia | RCT | 36 | NR | ≥3 M | Modafinil v. Placebo | 6 W | Patients | Individual |
Follow- Up | 18/36 | ||||||||
Nguyen et al., 2019 | Australia | RCT | 15 | // | NR | CBT v. TAU | 8 W | Psychologists* | Individual |
Van Heest et al., 2017 | USA | 1-Arm CT | 49 | NR | NR | Fatigue Management Course | 6 W | Clinical Psychologist | Individual |
West et al., 2019 | Denmark | RCT | 90 | NR | 7.6±8.3 (Treatment), 6.0±4.4 (Control) D | Naturalistic Lighting (Artificial Sunlight Spectrum) v. Standard Indoor Lighting | 45.3±22.1 (Treatment), 33.7±12.7 (Control) D | NA | Group |
Wu et al., 2017 | UK | 1-Arm CT | 12 | First/Recurrent | 3±24 M | Manualised Psychological Intervention | 7 S | Clinical Psychologist | Individual |
Most of the interventional studies have a medium to high risk of bias. Table 2 shows only two studies in white cells (indicating low risk of bias) but both have small sample size consisting of 34 (MIDAS study63–68) and 64 randomised patients61 respectively.
We identified 14 observational studies of which half had a prospective cohort design77–90 and the other half were cross-sectional surveys91–97. Three cross-sectional surveys were embedded within cohort studies91,94,97. Only one of the studies (NotFAST) had a follow-up report81–85. Details of all studies are reported in Table 3 as well as the Extended data.
Study name | Country | No. of centres | Design | No. of participants | Stroke type | Time after stroke** |
---|---|---|---|---|---|---|
ARCOS-IV | New Zealand | 4 | Cross-Sectional (in Cohort) | 256/2096* | First,Ischemic,Haemorrhagic,Undetermined | 4 Y |
Blomgren et al., 2019 | Sweden | 1 | Cohort | 296/411 | First,Recurrent, Ischemic | 7 Y |
Chen et al., 2018 | USA | 1 | Cohort | 128/203 | Ischemic, Haemorrhagic | 6 M |
Choi-Kwon et al., 2017a | South Korea | 1 | Cross-Sectional | 373/469 | Ischemic | 3 M |
Choi-Kwon et al., 2017b | South Korea | 1 | Cohort | 364/508 | Ischemic | 12 M |
Douven et al., 2017 | Netherlands | 2 | Cohort | 243/250 | First, Ischemic | 3, 6, 12 M |
Kuppuswamy et al., 2016 | UK | 3 | Cross-Sectional | 69 | First | 56.81±63 M |
LAS-1 | Sweden | 1 | Cross-Sectional (in Cohort) | 349 | NR | 6 Y |
Lau et al., 2017 | Hong Kong | 1 | Cross-Sectional | 191 | Ischemic | 3 M |
MacIntosh et al., 2017 | Canada | 4 | Cross-Sectional | 335 | Ischemic, Haemorrhagic | Within 6 M |
NotFAST | UK | 4 | Cohort | 268/371 | First | 4-6 W |
Follow-Up | 263/371 | 6 M | ||||
STROKDEM | France | 4 | Cohort | 153/179 | Ischemic, Haemorrhagic | 6 M |
van Rijsbergen et al., 2019 | Netherlands | 1 | Cross-Sectional (in Cohort) | 208 | First, Ischemic, Haemorrhagic, Recurrent | 3.3±0.5 M |
Wang et al., 2018 | China | 1 | Cohort | 634/703 | Ischemic | Within 3 D |
*For cohort studies, the left number shows the number of participants who finished follow-up, and the right number is the number of participants who started and took part in the study; for cross-sectional studies within cohort studies, the left number shows the number of participants in cross-sectional study and the right number is the number of participants in cohort study.
** Sometimes reported as time period and sometimes as mean and standard deviation across the studies.
Table 4 summarises the main finding of each interventional study all of which either have high risk of bias or small sample size. Such limitations make it hard to transfer the research findings to practice.
Study Name | Fatigue measure | Endpoint | Main post-stroke fatigue finding* |
---|---|---|---|
Chen et al., 2016 | Secondary: FAS | W 10 | There were no significant changes from baseline in FAS in either group (intervention: p=0.218; control: p=0.475; change between groups: p=0.198). |
Chen et al., 2019 | Fatigue VAS | D 5, 10 | Fatigue was not significantly associated with change in quality of life (β = −0.21,95% CI [−0.73~;0.31],p=0.42) and was not different in two groups. |
Delva, 2019 | FAS | D 3, M 1, 3 | The use of aspirin in high dose during 3 months with PSF diagnosis within the first days post-stroke is associated with decreasing of fatigue intensity due to FAS and modifying of post-stroke inflammatory response (р<0.05). |
Liu et al., 2016 | Primary: BFI | D28±5, 84±5 | Astragalus membranaceus group had improved fatigue in visit 1–28± 5 days – post- therapy (p=0.01) and in follow-up in 84 ± 5 days post-therapy (p=0.05). |
Liu et al., 2018 | Barthel Index | W 12 | Wuling can inhibit the release rate of inflammatory factor, reduce the expression level of related inflammatory factors and improve PSF (p<0.05). |
MIDAS | Primary: MFI | W 6, 7 | Modafinil group reported decrease in fatigue (β = −7.38, 95% CI [−21.76; −2.99],p<0.001) and improvement in quality of life (β = 11.81, 95% CI [2.31; 21.31], p=0.0148). |
M 12 | MFI and quality of life at baseline and their changes during treatment were correlated (β = −1.975, 95%CI [−3.082; −0.869], p < 0.001). Five of the patients who continued taking daily modafinil demonstrated 33–38 point simprovement in MFI compared to baseline. | ||
Nguyen et al., 2019 | Primary: FSS | M 2, 4 | CBT group demonstrated reduced fatigue relative to TAU post-therapy (β = 1.74,95%CI [0.70; 2.77],effect size (η2)=.52)and two months post-therapy (β =1.92, 95% CI [0.24; 3.60],effect size (η2)=.36). |
Van Heest et al., 2017 | Primary: FACIT- Fatigue | W 6, 12 | Participants showed reductions in fatigue at post-test (p<0.001; effect size (Cohen’s d) = 21.19) and maintained it at follow-up (p=0.315; effect size (Cohen’s d) = 0.23). |
West et al., 2019 | Primary: MFI | Discharge | At discharge, patients from the naturalistic light group experienced less fatigue than the indoor light group (diff = –20.6%, 95% CI [–35.0%; –3.0%],p = 0.025). |
Wu et al., 2017 | Secondary: FAS | S 6, 1, M 3 | Fatigue decreased post-treatment (mean difference=4.8, 95% CI [-2.1; 11.6], p = 0.15), in one-month assessment (mean difference=7.0, 95% CI [-0.8; 14.8], p = 0.07), and in three-month assessment (mean difference=9.3, 95% CI [1.4; 17.1]; p = 0.03). |
FAS: Fatigue Assessment Scale; VAS: Visual Analogue Scale; BFI: Brief Fatigue Index; MFI: Multidimensional Fatigue Inventory; FSS: Fatigue Severity Scale; FACIT: Functional Assessment of Chronic Illness Therapy; W: Weeks; D: Day; M: Month; S: Session; TAU: Treatment As Usual; CBT: Cognitive Behavioural Therapy.
The majority of observational studies investigated factors related to PSF including co-morbidities, physical and mental outcomes, illness characteristics, characteristics of interventions, and biomarkers (Table 5).
FSS: Fatigue Severity Scale; FIS: Fatigue Impact Scale; FACIT: Functional Assessment of Chronic Illness Therapy; FAS: Fatigue Assessment Scale; FAI: Fatigue Assessment Inventory; PSD: Post-Stroke Depression; CFS: Chalder Fatigue Scale; CLCE: Checklist for Cognitive and Emotional consequences following stroke
We identified six recent guidelines from three English-speaking countries including the UK49 and two North American countries (one from Canada48 and four from the USA98–101). Among these, the Canadian guideline was the most recent and the only one with comprehensive recommendations on PSF. The UK guideline will be updated in 2021. Half of these guidelines, that is, all those from USA, have not provided specific recommendations on PSF, as reported in Table 6. In almost all the guidelines, the reliance on ‘experts’ consensus’ is apparent because of the limited evidence base for PSF (Table 6).
AHA: American Heart Association; ASA: American Stroke Association; VA/DoD: Department of Veterans Affairs/Department of Defense; NICE: National Institute for Health and Care Excellence; CSBPR: Canadian Stroke Best Practice Recommendations by Management of Mood, Cognition and Fatigue Following Stroke Best Practice Writing Group/Heart & Stroke Canadian Stroke Best Practices and Quality Advisory Committee/Canadian Stroke Consortium; NR: Not Reported; RCT: Randomised Controlled Trial; CCT: Controlled Clinical Trial; CT: Clinical Trial; SR: Systematic Review.
We conducted this review to identify and summarise the most recent research studies on PSF since Hinkle et al.,’s review (2017)50. We therefore documented the interventional and observational research and clinical practice guidelines since March 2016. However, there were some key contributors to the weak evidence base: (i) recording and reporting only some contributing factors to PSF in observational studies, (ii) the heterogeneity of designed interventions, (iii) high risk of bias, (iv) small sample size in interventional studies, and (v) variety of outcome measures in both observational and clinical studies. This, in turn, is reflected in the quality of the clinical recommendations for PSF.
Despite the high prevalence of PSF2 and its obvious effects on treatment adherence102, in practice, only half of recent stroke guidelines have clinical recommendations on PSF. Of those that do, two guidelines provide only brief recommendations, and only one provides comprehensive recommendations, but these are based on low levels of evidence48. The weak evidence base and the need to rely on expert consensus is likely to be the main reason that PSF is generally not covered in the guidelines.
The dominance of single-centred interventional studies with small sample sizes and interventions delivered within a 12-week period may be the reasons for absence of follow-up studies. MIDAS (interventional)63–65 and NotFAST (observational)81–85 are the only recent studies with novel and potentially long-term findings with larger sample size (in case of MIDAS 2)103 or with the intention to design an intervention (NotFAST2)104.
While the observational studies reported the type of stroke, the interventional studies did not include this important data, which makes it difficult to summarise studies. Most of participants entered the interventional studies three-months after stroke. This is likely to be due to a number of reasons; for example, fatigue is not recognised immediately after a stroke, some studies want to ensure that participants have a continuous fatigue, and there is competition for recruitment in the early stages to more acute trials. However, one issue worth considering is whether the construct of PSF holds for fatigue experienced in research participants recruited years after their stroke, and whether this fatigue is a function of other issues. Future systematic reviews could address this issue by conducting sensitivity analyses comparing studies that include participants many years after their stroke with those including participants immediately after their stroke.
The variety of the interventions tested in studies and trials underlines the complexity of PSF and is an indication to researchers that future interventions will probably need to target multiple aspects of fatigue. While current reporting practice of interventions in RCTs included in our review is of concern (none followed TIDieR and two followed CONSORT), future studies should consider following reporting guidelines such as CONSORT and TIDieR for interventional studies, STROBE for observational studies, and RIGHT105, AGREE106, or CheckUP107 for clinical practice guidelines. In addition, harmonisaton of studies requires standard international guidelines regarding outcome measurements and time points for measuring PSF in a standard way to create a homogenous and collective body of evidence.
Among the observational studies, the population-based study from the stroke register in New Zealand91 and Sweden77 provides valuable insights about the link between co-morbidities and increased PSF in long-term (4–7 years). This, and other similar register-based studies, represent the added value of having high-quality data in health system databases for long-term observational and register-based studies108.
Psychologists delivered the psychotherapies in RCTs to individual patients and there was no intervention using online platforms as the media of delivery. This may be due to a number of reasons: it is usual to test the efficacy of an intervention face to face before moving to another medium; participants with stroke may have other problems which mean it is more difficult to deliver treatments online, e.g. communication issue and cognitive problems. Online delivery of such interventions is becoming more common in some clinical services, and new research is emerging109. Therefore, future reviews may wish to consider the impact of such interventions delivered online.
Fatigue Severity Scale (FSS) was the main outcome measure for PSF in observational studies, whereas Fatigue Assessment Scale (FAS) was used more frequently than other measures in interventional studies. Bearing in mind that both these PSF measurement scales are valid and reliable, the main reason that the FSS has been used more frequently is probably because it is now seen as a way to compare different studies: in simple terms, researchers use it because other researchers have used it. It is also relatively straight forward to complete.
Only one of the observational studies and half of the interventional studies were registered in clinical trial registers, with the remaining unregistered trials potentially introducing bias in selective reporting of outcomes110,111. One of the interventional studies was registered retrospectively with potential for the same bias69,70.
It is possible that we overlooked studies that did not report PSF in the searchable part of the paper or if the report was not indexed in the searched databases. In such cases, we invite readers of this review to contact us or comment on the paper online.
Due to the challenges we faced in identifying the search strategies in the previous review when conducting this update, we have explicitly documented our search criteria and strategies so that this review can be easily repeated and updated by future researchers. We feel this is a key strength of this review. We also feel that the use of automation tools such as Rayyan and RobotReviewer for this evidence synthesis was a strength in terms of saving time and other resources while still maintaining the quality of the review. Finally involving a multi-disciplinary team of clinicians and methodologists (information specialist and systematic reviewer) allowed us to consider both the clinical and methodological aspects of the studies in this review.
The current trend of research on PSF shows the continued importance of this topic globally. Our review identified a weak evidence base that highlights the need for more research that could have the following characteristics: I) studies to design and test multi-component interventions for PSF; and II) Robust RCTs with adequate sample sizes to produce the evidence for recommendations in guidelines. From our current knowledge on PSF, none of the recent studies are robust enough to change current clinical practice.
Open Science Framework: Post-Stroke Fatigue: A Scoping Review, https://doi.org/10.17605/OSF.IO/XJKCS112.
Registration DOI: https://doi.org/10.17605/OSF.IO/XJKCS
This project contains the following underlying data:
Open Science Framework: Post-Stroke Fatigue: A Scoping Review, https://doi.org/10.17605/OSF.IO/XJKCS112.
This project contains the following extended data:
Open Science Framework: PRISMA-ScR checklist for ‘Post-stroke fatigue: a scoping review’, https://doi.org/10.17605/OSF.IO/XJKCS112.
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
We are grateful to Dr Fiona Nouri for her critical comments and proof-reading of the revised version of this paper before publication.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Yes
Is the statistical analysis and its interpretation appropriate?
Not applicable
Are the conclusions drawn adequately supported by the results presented in the review?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Stroke rehabilitation
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Yes
Is the statistical analysis and its interpretation appropriate?
Not applicable
Are the conclusions drawn adequately supported by the results presented in the review?
Yes
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 25 Aug 20 |
read | |
Version 1 07 Apr 20 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)